Novogen names two NEDs

Wednesday, 10 June 2015


    Dual-listed drug discovery and development company, Novogen, has appointed two new non-executive directors. Bryce Carmine and Ian Phillips will extend the board to six members, inclusive of five non-executive directors and an executive chair.

    Carmine comes with 36 years of experience and is currently chair and CEO for HaemaLogiX, a newly formed Sydney-based biotechnology company.

    Phillips comes with a background in wholesale banking at a senior executive level. He will chair the board's strategic planning committee.


    Aurizon Holdings has announced it will appoint Tim Poole as its new chair, following the planned retirement of John B Prescott AC FAICD in September.

    Poole was previously chairman of rival rail business Asciano and currently heads AustralianSuper's investment committee. He will be appointed to Aurizon's board of directors from 1 July and will take over from Prescott on 1 September.


    Electrical infrastructure firm, SCEE has appointed Karl Paganin as an independent non-executive director.

    Paganin has 15 years experience in investment banking, specialising in transaction structuring and equity capital markets.

    Prior to that he was director of major projects and senior legal counsel for private trading company, Heytesbury.

    Latest news

    This is of of your complimentary pieces of content

    This is exclusive content.

    You have reached your limit for guest contents. The content you are trying to access is exclusive for AICD members. Please become a member for unlimited access.